Tractivus is live on Capital Cell
Barcelona – April 2019. Tractivus SL is pleased to announce that we launch a financial round through Capital Cell to manufacture and validate our products for the regulatory process ... Read more
Tractivus SL has been granted with the R&D Spanish program “RETOS 2017”
Barcelona – December 2018. Tractivus SL is pleased to announce that Ministry of Science, Innovation and Universities (Spanish government), through the European Regional Development Fund (FEDER, European Union), has funded the Development of an antibacterial urinary catheter – BioUrostent project of Tractivus... Read more
Tractivus participates in QuirofAM project from RIS3CAT community
Barcelona – May 2018. Tractivus is pleased to announce its participation in the RIS3CAT community and it has been granted with funds for the development of the QuirofAM project in collaboration with other entities of the Community such as other SMEs, large companies, research centres and universities of the Catalan innovation system... Read more
Tractivus has been granted with the NEOTEC Funding for 2016-2017
Barcelona – July 2016. Tractivus is pleased to announce that Centro para el Desarrollo Tecnológico Industrial (CDTI) has granted funding to Tractivus SL for... Read more
IDIBELL and IQS license a technology to Tractivus to develop a new tracheal stent
Barcelona – June 2016. IQS and IDIBELL license a technology to Tractivus to enhance a new tracheal stent, a revolution in current prostheses to treat the problems of post-implantation therapy and improve... Read more
Barcelona - May 2015. Tractivus project was enrolled in the I-CORPS program from the National Science Foundation (NSF, US Goverment) for 3 months between San Francisco (Berkeley UC) and Barcelona. This progam was organized by Fundació Catalana per la Recerca i la Innovació, Generalitat de Catalunya (FCRi) and consist on a set of activities and programs that prepares scientists and engineers to extend their focus beyond the laboratory and broadens the impact of select basic-research projects.
The Bay Area NSF Innovation Corps (I-Corps™) is a collaboration between the University of California Berkeley, University of California San Francisco and Stanford University and funded by the National Science Foundation that offers an educational program to accelerate the commercialization of science and fosters technology entrepreneurship.
I-Corps training is propelling early stage startups to success and to help to find a scalable business model for a startup through a rigorous Customer Discovery process. The course is based on the Lean Launchpad methodology pioneered by UC Berkeley and Stanford Faculty member Steve Blank. Companies that complete this training, improve their chances of getting sizable, non-dilutive grants from 16% (without course) to >65% (after course).
Barcelona - May 2015. Tractivus project was worthy of the Llavor Ajut from Generalitat de Catalunya, European Regional Development Fund to validate the business idea and technology to a productivity level facilitating the implementation of it by developing the first prototype to test its activity through a compassionate use.
European Congress for Bronchology and Interventional Pulmonology
Chris Bollinger Award
Barcelona - April 2015. Tractivus technology, as a GEMAT project, was awarded with 1st prize of Chris Bollinger Award during the 3rd European Congress for Bronchology and Interventional Pulmonology in Barcelona in 2015. The attendances valorate the Tractivus technology as a breakthrough on tracheal stents field and one of the most innovative and curative solutions to treat trachea pathologies.
Barcelona - December 2014. Tractivus, as a GEMAT project, was enroled in the Bioemprenedor XXI (7th edition) in 2014 organized by Biocat (Generalitat de Catalunya), Barcelona Activa (Ajuntament de Barcelona) i la Caixa (CaixaBank). During the development of the program, about 6 months, Tractivus validates the business plan with advisors, mentors and investors. Finally, the project was prized as 2nd finalist for the best business plan for biotech companies of 2014. Read more